Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
OTC Drugs

Church & Dwight Counts On Line Extensions To Drive 2011 Growth

This article was originally published in The Tan Sheet

  • News

Executive Summary

Church & Dwight looks to line extensions for brands including First Response pregnancy tests and Trojan condoms to help offset possible losses in the oral care segment caused by competitors' pricing war.

You may also be interested in...



C&D’s Naturals Could Help Retain Orajel Customers After Benzocaine Warning

Church & Dwight’s Baby Orajel Naturals could fill a potential void in the teething relief market created by FDA’s recent warning children under 2 years should not use the painkiller benzocaine.

C&D’s Naturals Could Help Retain Orajel Customers After Benzocaine Warning

Church & Dwight’s Baby Orajel Naturals could fill a potential void in the teething relief market created by FDA’s recent warning children under 2 years should not use the painkiller benzocaine.

C&D’s Naturals Could Help Retain Orajel Customers After Benzocaine Warning

Church & Dwight’s Baby Orajel Naturals could fill a potential void in the teething relief market created by FDA’s recent warning children under 2 years should not use the painkiller benzocaine.
Table

View full table

Related Content

Pink Sheet Pink Sheet HBW Insight Pink Sheet Pink Sheet Pink Sheet Pink Sheet

Topics

Tags:
OTC Drugs
UsernamePublicRestriction

Register

PS104859

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By